Avelox (Moxifloxacin, BAY12-8039) + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
QTc Evaluation
Conditions
QTc Evaluation, Electrocardiography
Trial Timeline
Nov 1, 2009 → Jun 1, 2010
NCT ID
NCT01014247About Avelox (Moxifloxacin, BAY12-8039) + Placebo
Avelox (Moxifloxacin, BAY12-8039) + Placebo is a phase 1 stage product being developed by Bayer for QTc Evaluation. The current trial status is completed. This product is registered under clinical trial identifier NCT01014247. Target conditions include QTc Evaluation, Electrocardiography.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01014247 | Phase 1 | Completed |
| NCT00473460 | Phase 3 | Completed |
Competing Products
5 competing products in QTc Evaluation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler | AstraZeneca | Phase 1 | 33 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |
| Sativex + Sativex + Sativex + Placebo + Marinol + Marinol | Jazz Pharmaceuticals | Phase 1 | 30 |
| ETC-1002 | Esperion Therapeutics | Phase 1 | 28 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |